Adam Master
Nencki Institute of Experimental Biology
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Adam Master.
PLOS ONE | 2011
Joanna Boguslawska; Anna Wojcicka; Agnieszka Piekiełko-Witkowska; Adam Master; Alicja Nauman
Type 1 iodothyronine deiodinase (DIO1) catalyses the conversion of prohormone thyroxine to the active thyroid hormone 3,3′,5-triiodothyronine (T3), important regulator of cell proliferation and differentiation. DIO1 expression is reduced in the most common type of kidney neoplasia, clear cell Renal Cell Carcinoma (ccRCC). MicroRNAs are small, non-coding RNAs that regulate gene expression at posttranscriptional levels. The aim of this study was to analyze the potential regulation of DIO1 expression by microRNAs in ccRCC. Bioinformatic analysis revealed that 3′UTR of the human DIO1 gene transcript contains miR-224 and miR-383 target sites, which are conserved across mammalian species. Semi-quantitative real-time PCR was used to analyze the expression of miR-224 and miR-383 in 32 samples of ccRCC tumors (T) and in 32 matched control (C) samples. We observed statistically significant (p = 0.0002) more than four fold increase in miR-224 expression and nearly two fold increase in miR-383 expression in samples T compared to samples C. Tumor specific changes in expression of miR-224 negatively correlated with changes in DIO1 expression and intracellular T3 concentration. Transfection of HeLa cell line with miR-224 and miR-383 suppressed the activity of a luciferase reporter containing the 3′UTR of DIO1. This was abolished when constructs mutated at the miR-224 and miR-383 target sites were used instead, indicating that miR-224 and miR-383 directly bind to DIO1 3′UTR. Finally, induced expression of miR-224 in Caki-2 cells resulted in significant (p<0.01) reduction of DIO1 mRNA. This study provides a novel miRNA-mediated regulatory mechanism of DIO1 expression in ccRCC.
PLOS ONE | 2014
Anna Wojcicka; Agnieszka Piekielko–Witkowska; Hanna Kędzierska; Beata Rybicka; Piotr Popławski; Joanna Boguslawska; Adam Master; Alicja Nauman
Abstract Thyroid hormone receptor beta (THRB) gene is commonly deregulated in cancers and, as strengthened by animal models, postulated to play a tumor-suppressive role. Our previous studies revealed downregulation of THRB in clear cell renal cell carcinoma (ccRCC), but the culpable mechanisms have not been fully elucidated. Since epigenetic regulation is a common mechanism influencing the expression of tumor suppressors, we hypothesized that downregulation of THRB in renal cancer results from epigenetic aberrances, including CpG methylation and microRNA-dependent silencing. Our study revealed that ccRCC tumors exhibited a 56% decrease in THRB and a 37% increase in DNA methyltransferase 1 (DNMT1) expression when compared with paired non-neoplastic control samples. However, THRB CpG methylation analysis performed using BSP, SNaPshot and MSP-PCR consistently revealed no changes in methylation patterns between matched tumor and control samples. In silico analysis resulted in identification of four microRNAs (miR-155, miR-425, miR-592, and miR-599) as potentially targeting THRB transcript. Luciferase assay showed direct binding of miR-155 and miR-425 to 3′UTR of THRB, and subsequent in vivo analyses revealed that transfection of UOK171 cell line with synthetic miR-155 or miR-425 resulted in decreased expression of endogenous TRHB by 22% and 64%, respectively. Finally, real-time PCR analysis showed significant upregulation of miR-155 (354%) and miR-425 (162%) in ccRCC when compared with matched controls. Moreover, microRNA levels were negatively correlated with the amount of THRB transcript in tissue samples. We conclude that CpG methylation is not the major mechanism contributing to decreased THRB expression in ccRCC. In contrast, THRB is targeted by microRNAs miR-155 and miR-425, whose increased expression may be responsible for downregulation of THRB in ccRCC tumors.
PLOS ONE | 2016
Aneta Koronowicz; Aneta Kopeć; Adam Master; Sylwester Smoleń; Ewa Piątkowska; Renata Bieżanowska-Kopeć; Iwona Ledwożyw-Smoleń; Łukasz Skoczylas; Roksana Rakoczy; Teresa Leszczyńska; Mirosław Pysz
Although iodization of salt is the most common method used to obtain iodine-enriched food, iodine deficiency disorders are still a global health problem and profoundly affect the quality of human life. Iodine is required for the synthesis of thyroid hormones, which are crucial regulators of human metabolism, cell growth, proliferation, apoptosis and have been reported to be involved in carcinogenesis. In this study, for the first time, we evaluated the effect of iodine-biofortified lettuce on transcriptomic profile of Caco-2 cancer cell line by applying the Whole Human Genome Microarray assay. We showed 1326 differentially expressed Caco-2 transcripts after treatment with iodine-biofortified (BFL) and non-fortified (NFL) lettuce extracts. We analysed pathways, molecular functions, biological processes and protein classes based on comparison between BFL and NFL specific genes. Iodine, which was expected to act as a free ion (KI-NFL) or at least in part to be incorporated into lettuce macromolecules (BFL), differently regulated pathways of numerous transcription factors leading to different cellular effects. In this study we showed the inhibition of Caco-2 cells proliferation after treatment with BFL, but not potassium iodide (KI), and BFL-mediated induction of mitochondrial apoptosis and/or cell differentiation. Our results showed that iodine-biofortified plants can be effectively used by cells as an alternative source of this trace element. Moreover, the observed differences in action of both iodine sources may suggest a potential of BFL in cancer treatment.
Ppar Research | 2017
Aneta Koronowicz; Paula Banks; Adam Master; Dominik Domagała; Ewelina Piasna-Słupecka; Mariola Drozdowska; Elżbieta Sikora; Piotr Laidler
In our previous study, we showed that fatty acids from CLA-enriched egg yolks (EFA-CLA) reduced the proliferation of breast cancer cells; however, the molecular mechanisms of their action remain unknown. In the current study, we used MCF-7 breast cancer cell line to determine the effect of EFA-CLA, as potential ligands for peroxisome proliferator-activated receptors (PPARs), on identified in silico PPAR-responsive genes: BCAR3, TCF20, WT1, ZNF621, and THRB (transcript TRβ2). Our results showed that EFA-CLA act as PPAR ligands with agonistic activity for all PPAR isoforms, with the highest specificity towards PPARγ. In conclusion, we propose that EFA-CLA-mediated regulation of PPAR-responsive genes is most likely facilitated by cis9,trans11CLA isomer incorporated in egg yolk. Notably, EFA-CLA activated PPAR more efficiently than nonenriched FA as well as synthetic CLA isomers. We also propose that this regulation, at least in part, can be responsible for the observed reduction in the proliferation of MCF-7 cells treated with EFA-CLA.
Biochimica et Biophysica Acta | 2010
Adam Master; Anna Wojcicka; Agnieszka Piekiełko-Witkowska; Joanna Boguslawska; Piotr Popławski; Zbigniew Tanski; Veerle Darras; Graham R. Williams; Alicja Nauman
Acta Biochimica Polonica | 2007
Alicja Nauman; Olga Turowska; Piotr Popławski; Adam Master; Zbigniew Tanski; Monika Puzianowska-Kuznicka
Thyroid | 2009
Agnieszka Piekiełko-Witkowska; Adam Master; Anna Wojcicka; Joanna Boguslawska; Izabela Brózda; Zbigniew Tanski; Alicja Nauman
Acta Biochimica Polonica | 2008
Pawel Wisniewski; Adam Master; Bozena Kaminska
Archive | 2010
Joanna Boguslawska; Adam Master; Anna Wojcicka; Piotr Popławski; Agnieszka Piekiełko-Witkowska; Alicja Nauman
Postępy Nauk Medycznych | 2008
Alicja Nauman; Agnieszka Piekiełko-Witkowska; Olga Turowska; Piotr Popławski; Adam Master; Zbigniew Tanski; Joanna Lampkowska; Anna Wojcicka; Izabela Brózda; Monika Puzianowska-Kuźnicka